- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04844970
Anamorelin Study for Advanced Pancreatic Cancer
A Randomized, Double-blind, and Placebo Controlled Multicenter Phase II Trial Evaluating Anamorelin in the Prevention of Cancer Induced-Weight Loss and Anorexia in Patients Receiving First-line Treatment of Advanced Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Anorexia and cachexia are common clinical sequelae of uncontrolled, metastatic cancer. These effects can impair physical function, reduce quality of life, impair tolerability of anticancer therapy, and reduce survival. Anorexia and cachexia are especially challenging problems in patients diagnosed with metastatic pancreatic cancer. With an annual incidence approaching 50,000 patients in the U.S. alone, pancreatic cancer has an annual mortality of approximately 40,000 patients with most individuals succumbing to their disease within two years. Between 70-80% of patients with metastatic pancreatic cancer experience cancer cachexia, which has been associated with reduced survival, increased risk of disease progression, and impaired chemotherapy tolerance.
Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects. Several randomized, double-blind, clinical trials in cancer patients have shown that anamorelin HCL is safe, efficacious and increases lean body mass, bodyweight, and appetite. Investigators propose to test anamorelin HCL administered with chemotherapy in the first-line treatment of locally advanced unresectable and metastatic pancreatic cancer.
The study is a randomized, placebo controlled multicenter, Phase II trial to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 patients with be enrolled in a 1:1 randomization to anamorelin HCL 100mg per day given concurrently with first-line chemotherapy compared to chemotherapy alone. Patients randomized to anamorelin HCL will take it daily for 24 weeks starting one day prior to chemotherapy. All patients will undergo an assessment by a certified nutritionist at or prior to their first cycle of chemotherapy. Both body weight and appetite will be measured at enrollment as well as at the initiation of chemotherapy. Patients will be stratified by degree of weight loss in the six months prior to enrollment, choice of first-line chemotherapy, and by baseline score of 5-item Anorexia Symptom Scale.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Essence D Maston, PhD
- Phone Number: 7817443495
- Email: Essence.D.Maston@lahey.org
Study Locations
-
-
Massachusetts
-
Burlington, Massachusetts, United States, 01805
- Recruiting
- Lahey Hospital & Medical Center
-
Contact:
- Essence D Maston, PhD
- Phone Number: 781-744-3495
- Email: Essence.d.maston@lahey.org
-
Contact:
- Julia C Roache
- Phone Number: 7817443055
- Email: Julia.Roache@lahey.org
-
Principal Investigator:
- Krishna S Gunturu, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed written informed consent
- Female or male ≥18 years of age
- Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) unresectable or metastatic pancreatic adenocarcinoma
- Body mass index < 20 kg/m2 with involuntary weight loss or >5% within 6 months prior to screening
- Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of ≤ 17 points on the 5-item Anorexia Symptom Scale and ≤ 37 points on the 12-item FAACT A/CS
- Subjects eligible to receive first line palliative chemotherapy
- ECOG performance status 0 or 1 at screening
- Acceptable hepatic function as defined by total bilirubin < 1.6 mg/dl unless associated with Gilbert syndrome, then total bilirubin < 2 x ULN. AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN or if hepatic metastases are present ≤ 5 x ULN
- Appropriate treatment with pancreatic enzyme replacement prior to trial initiation
Female subjects shall be:
- of non-childbearing potential or
- of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to first dose of investigational product.
- The patient must be willing and able to comply with the protocol tests and procedures All inclusion criteria will be checked at screening visit (Visit 1).
Exclusion Criteria:
- Patient with other forms of pancreatic cancer (e.g. neuroendocrine tumors)
- Patient undergoing major surgery within 4 weeks of randomization or plans to undergo major surgery during study period.
- Women who are pregnant or breastfeeding
- Patient with alternative cause of cachexia as determined by the investigator including: a) severe COPD requiring O2, b) severe heart failure (NYHA Class III- IV), c) second malignancy
- Reversible causes of reduced food intake as determined by the investigator including but not limited to: severe mucositis (>=NCI CTCAE grade 3), mechanical obstruction, severe nausea, vomiting, or diarrhea (>=NCI CTCAE grade 3)
- Patient unable to swallow pills
- Patient with history of bariatric surgery, gastrectomy, or malabsorption disorder (gastritis, esophagitis)
- Patient with recent use of CYP3A4 inhibitors
- Patient with current daily use of therapies that may increase the QRS interval durations
- Patient currently taking medications/compounds intended to increase appetite or decrease weight loss (e.g. testosterone, megestrol acetate, cannabis products, methylphenidate, corticosteroids, olanzapine, mirtazapine (allowed if >4 weeks of use as therapy for depression)
- Patient with current use of tube feeding or parenteral feeding
- Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring drainage, edema or evidence of ascites
Patient with uncontrolled or significant cardiovascular disease, including:
- History of myocardial infarction within the past 3 months
- A-V block of second or third degree (may be eligible if currently have a pacemaker)
- Unstable angina
- Congestive heart failure within the past 3 months, if defined as NYHA class III-IV
- Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, or torsade de pointes)
- Uncontrolled hypertension (blood pressure >150 mm Hg systolic and >95 mm Hg diastolic)
- Heart rate < 50 beats per minute on pre-entry electrocardiogram and patient is symptomatic
- Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus
- Patient with uncontrolled pain.
- Any condition, including the presence of laboratory abnormalities, which in the Investigator's opinion, places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- Enrollment in a previous study with anamorelin HCl
- Enrollment in another clinical trial during the time of this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anamorelin
Patients randomized to anamorelin HCL will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
|
Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects.
|
Placebo Comparator: Placebo
Patients randomized to placebo will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
|
Anamorelin placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight change
Time Frame: 25 weeks
|
demonstrate superiority of anamorelin HCl dosed at 100mg per day vs. placebo on body weight gain and improvement in anorexia symptoms in patients undergoing first-line chemotherapy for incurable pancreatic cancer.
|
25 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anorexia Questionnaire
Time Frame: from baseline to week 13
|
Absolute change in the FAACT 5 item Anorexia Symptom Score from baseline at week
|
from baseline to week 13
|
Survival
Time Frame: 25 weeks
|
Overall Survival
|
25 weeks
|
Radiologic Response to Chemotherapy
Time Frame: from baseline to week 13
|
Chemotherapy response will be evaluated by RECIST criteria
|
from baseline to week 13
|
Weight gain
Time Frame: from baseline to week 25 (end of the study)
|
from baseline to week 25 (end of the study)
|
|
Fatigue Questionnaire
Time Frame: from baseline to week 13
|
Change in FACIT-F questionnaire, fatigue subscale
|
from baseline to week 13
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: from baseline to week 25 (end of study)
|
expected toxicities for Chemotherapies (FOLFIRINOX and Gemcitabine/Nab-Paclitaxel) will be assessed by CTCAE v5.0
|
from baseline to week 25 (end of study)
|
AEs
Time Frame: from baseline to week 25 (end of study)
|
AEs that are related to the drug
|
from baseline to week 25 (end of study)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Unplanned visits
Time Frame: from baseline to week 25 (end of the study)
|
number of unplanned visits for symptom management as defined by unscheduled clinic visits, emergency department visits, or hospitalizations
|
from baseline to week 25 (end of the study)
|
Chemotherapy Dose change
Time Frame: from baseline to week 13
|
Percent change in dose intensity of chemotherapy as defined by percent reduction in anticipated chemotherapy dose as determined y the treating physician
|
from baseline to week 13
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LHMC 20193054
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Pancreatic Cancer
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
Dana-Farber Cancer InstitutePatient-Centered Outcomes Research Institute; National Cancer Institute (NCI); Alliance for Clinical Trials in OncologyCompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal AdenocarcinomaUnited States
-
University Hospital HeidelbergGerman Cancer Research CenterCompletedColorectal Cancer Metastatic | Pancreatic Cancer MetastaticGermany
-
HonorHealth Research InstituteUniversity of Arizona; Agenus Inc.; Translational Genomics Research InstituteNot yet recruitingPancreatic Cancer Metastatic | Pancreatic Adenocarcinoma MetastaticUnited States
-
Pancreatic Cancer Action NetworkActive, not recruitingMetastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic CancerUnited States
-
Joachim Aerts, MD PhDCompletedMetastatic Pancreatic CancerNetherlands
-
Georgetown UniversityNational Cancer Institute (NCI); Mayo Clinic; Emory University; Indiana University and other collaboratorsTerminatedMetastatic Colorectal Cancer | Pancreatic Adenocarcinoma | Colorectal Adenocarcinoma | Metastatic Pancreatic CancerUnited States
Clinical Trials on Anamorelin Hydrochloride
-
Helsinn Healthcare SACompletedNon Small Cell Lung Cancer | Cachexia; CancerUnited States, Russian Federation, Bulgaria, Hungary, Italy, Romania, Serbia
-
Tufts UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
Helsinn Therapeutics (U.S.), IncCompletedNon-Small Cell Lung Cancer | CachexiaPoland, United States, Israel, Russian Federation, Hungary, Australia, United Kingdom
-
Helsinn Therapeutics (U.S.), IncCompletedNon-Small Cell Lung Cancer | CachexiaPoland, Ukraine, United States, Belgium, Spain, Belarus, Slovenia, Serbia, Canada, Russian Federation, Australia, Hungary, Germany, Czechia, France, Israel, Italy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnorexia | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8United States
-
Helsinn Healthcare SACompletedNon Small Cell Lung Cancer | Cachexia; CancerUnited States, Croatia, Australia, Belgium, Russian Federation, Poland, Romania, Ukraine
-
Helsinn Therapeutics (U.S.), IncCompletedCarcinoma, Non-Small-Cell LungUnited States, India
-
VA Office of Research and DevelopmentHelsinn Therapeutics (U.S.), IncTerminated
-
Helsinn Therapeutics (U.S.), IncCompletedNon-Small Cell Lung Cancer | CachexiaUnited States, Poland, Ukraine, Belgium, Germany, Spain, Belarus, Slovenia, Serbia, Netherlands, Canada, Russian Federation, Hungary, Czechia, France, Italy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingWeight Loss | Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Cancer Fatigue | C-Reactive Protein MeasurementUnited States